Patents Issued in January 9, 2020
  • Publication number: 20200009037
    Abstract: The invention relates to cosmetic formulations and new peptide related entities designed for the cosmetic treatment of the human skin. In more detail, the invention is related to peptides that target CD90 positive tissue cells and correspond to or derive from the partial sequence of erythropoietin (EPO) but do not substantially elicit a hematopoietic but a tissue regenerative and protective effect. In particular, the invention discloses EPO-derived tissue-protective peptides in functional relation to lipid structures and agents that trigger vasculature relaxation and promote transdermal transport of the polypeptide entities to the targeted skin cells.
    Type: Application
    Filed: September 24, 2019
    Publication date: January 9, 2020
    Inventor: Augustinus BADER
  • Publication number: 20200009038
    Abstract: The present invention provides threads of hyaluronic acid, and/or derivatives thereof, methods of making thereof and uses thereof, for example, in aesthetic applications (e.g., dermal fillers), surgery (sutures), drug delivery, etc.
    Type: Application
    Filed: August 30, 2019
    Publication date: January 9, 2020
    Inventors: Geoffrey C. GURTNER, Kenneth N. HORNE, Jayakumar RAJADAS
  • Publication number: 20200009039
    Abstract: A method for treating hair comprising applying primer(s) and cationic polymer(s) onto a user's hair for improving the styling of the hair in a more manageable and reliable manner and for enhancing the stability of the final style obtained.
    Type: Application
    Filed: October 5, 2018
    Publication date: January 9, 2020
    Inventors: Lars Siegfried Dahne, Mathias Kurt Herrlein, Tatjana Schaefer, Judith Hagios, Mandy Hecht, Moritz Klickermann
  • Publication number: 20200009040
    Abstract: The invention provides topical formulations and methods comprising charged bioactive agents complexed with amphipol polymers for dermal and transdermal delivery, optionally further including TJ-modulating peptides.
    Type: Application
    Filed: February 7, 2018
    Publication date: January 9, 2020
    Applicant: MYOCEPT INC.
    Inventor: Lars Erik PETERS
  • Publication number: 20200009041
    Abstract: The present invention relates to a polymer comprising: (a) from 9.49 mol-% to 98 mol-% repeating units according to Formula (1) wherein at least 10 wt.-% of the repeating units according to Formula (1) comprise from 28 wt.-% to 100 wt.-% bio-based carbon content, relative to the total mass of carbon in the repeating unit according to Formula (1), measured according to standard ASTM D6866-12, Method B; (b) from 0.01 mol-% to 5 mol-% crosslinking or branching units; (c) from 0.01 mol-% to 88.52 mol-% of repeating neutral structural units; (d) from 1.98 mol-% to 20 mol-% of repeating anionic structural units, wherein the repeating anionic structural units result from the incorporation of a monomer comprising at least one carboxylate anion, and wherein the repeating anionic structural units are different from units (a).
    Type: Application
    Filed: December 4, 2017
    Publication date: January 9, 2020
    Applicant: Clariant International Ltd.
    Inventors: Dirk FISCHER, Christoph KAYSER, Gundula STARKULLA
  • Publication number: 20200009042
    Abstract: A system and method of improving the condition of skin by reducing or eliminating wrinkles and hyperpigmentation is presented. The method delivers stem cells into the dermal layer of the skin to increase the number and density of fibroblasts in the dermal layer which in turn increases collagen, elastin and hyaluronic acid production to improve the appearance of the skin. The method includes constructing a scaffolding within microperforations in the skin and administering a therapeutically effective amount of stem cells to the skin which are supported on the scaffolding to remain in the microperforations for weeks thus allowing the dermal layer of skin to rebuild to a more youthful state.
    Type: Application
    Filed: January 30, 2019
    Publication date: January 9, 2020
    Inventor: Robert Mehran Dean
  • Publication number: 20200009043
    Abstract: The present invention relates to a cosmetic composition for keloid scar improvement. The cosmetic composition for keloid scar improvement according to the present invention contains a sponge cucumber extract and a pineapple extract as active ingredients. Through the above constitution, the cosmetic composition is prepared by using natural extracts, so that the present invention can have an excellent effect of improving keloid scars, cause fewer side effects, have antibacterial and anti-inflammatory actions of saponin and flavonoid components of sponge cucumber, relieve pain through the alleviation of skin itchiness and skin redness, and alleviate skin dryness through a moisturizing effect.
    Type: Application
    Filed: March 22, 2018
    Publication date: January 9, 2020
    Inventor: Young Oh Park
  • Publication number: 20200009044
    Abstract: The invention provides artificial tear compositions, artificial tear-gel compositions, contact lens storage compositions, contact lens treatment compositions, ophthalmological drug vehicle compositions and topical drug vehicle compositions comprising one or more nonionic surfactants with one or more non-Newtonian viscosity enhancing excipients and one or more of a polyol and or an electrolyte and methods of their use.
    Type: Application
    Filed: September 19, 2019
    Publication date: January 9, 2020
    Inventor: Gerald Horn
  • Publication number: 20200009045
    Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
    Type: Application
    Filed: July 17, 2019
    Publication date: January 9, 2020
    Inventor: Mir Imran
  • Publication number: 20200009046
    Abstract: A food for improving intestinal environment by promoting proliferation of intestinal bifidobacteria is described herein. The food for improving intestinal environment can contain a combination of (1) an enteric composition containing an amino acid or a salt thereof and (2) an indigestible polysaccharide or a composition containing an indigestible polysaccharide.
    Type: Application
    Filed: September 23, 2019
    Publication date: January 9, 2020
    Applicant: AJINOMOTO CO., INC.
    Inventors: Keishi Kameyama, Momoka Tsuneyoshi
  • Publication number: 20200009047
    Abstract: A mesh bag filled with decarboxylated marijuana and/or marijuana concentrates designed to fit in virtually any spirits bottle. Once submerged the alcohol absorbs the cannabinoid oils (THC/CBDs) and thereby become psycho-active. The Marijuana Spirit Spiker is a food grade mesh bag filled with decarboxylated marijuana and/or marijuana concentrates. The mesh bag is designed to fit into virtually any ‘hard’ alcohol bottle and be added to the bottle by the consumer after purchase. Once submerged in alcohol, the marijuana and/or marijuana concentrates in the MSS absorbs into the alcohol. The alcohol will absorb the cannabinoid oils (THC/CBDs) and become psycho-active.
    Type: Application
    Filed: July 6, 2018
    Publication date: January 9, 2020
    Inventor: Adam Franklin Dickie
  • Publication number: 20200009048
    Abstract: Described herein is a sugar-depleted fruit or vegetable juice product, wherein said juice product is a fruit or vegetable juice or juice-retaining fruit or vegetable derived matter, wherein said juice product contains at least about 5 g/l gluconic acid and said juice product contains any two or three, of (i) at least about 0.5 g/l Ca2+, (ii) at least about 1 g/l K+, and (iii) at least about 0.1 g/l Mg2+. Also provided are methods of producing the same and the use thereof to assist in maintaining the health and well-being of a subject and in the treatment and prevention of medical ailments, specifically those associated with the over-consumption of glucose and/or sucrose or inappropriate metabolism of glucose, e.g. metabolic syndrome, diabetes mellitus type II, obesity, dyslipidemia, insulin resistance, hypertension and liver steatosis.
    Type: Application
    Filed: September 18, 2019
    Publication date: January 9, 2020
    Inventors: Jurgen Schrezenmeir, Svein Halvor Knutsen, Simon Ballance
  • Publication number: 20200009049
    Abstract: Improved therapeutic sclerosing microfoams and methods and devices for making them are provided that have advantage in producing a consistent profile injectable foam with minimal input by the physician yet using high volume percentages of blood dispersible gases, thus avoiding use of potentially hazardous amounts of nitrogen.
    Type: Application
    Filed: February 26, 2019
    Publication date: January 9, 2020
    Inventors: Tariq OSMAN, Sheila Bronwen SHILTON-BROWN, David Dakin lorwerth WRIGHT, Anthony David HARMAN, Timothy David BOORMAN
  • Publication number: 20200009050
    Abstract: The present invention relates to a pharmaceutical composition comprising the combination of (i) a biocompatible nanoparticle and of (ii) a pharmaceutical compound of interest, to be administered to a subject in need of such a compound of interest, wherein the nanoparticle potentiates the compound of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm, and its absolute surface charge value is of at least 10 mV (|10 mV|). The invention also relates to such a composition for use for administering the compound of interest to a subject in need thereof, wherein the nanoparticle and the compound of interest are to be administered to said subject between more than 5 minutes and about 72 hours from each other.
    Type: Application
    Filed: August 29, 2019
    Publication date: January 9, 2020
    Inventors: AGNÈS POTTIER, LAURENT LEVY, MARIE-EDITH MEYRE, AUDREY DARMON, MATTHIEU GERMAIN
  • Publication number: 20200009051
    Abstract: A shelf stable liposomal based oral rehydration formulation as a mixture has an improved beverage rehydration index performance. The liposomal rehydration salt formulation prevents severe dehydration, maintains body electrolytes and fluids in a human, and rehydrates a human. The formulation includes less than 0.4% phospholipids, having an average size less than 270 nm and an osmolality of about 200 mOsm/kg.
    Type: Application
    Filed: August 29, 2019
    Publication date: January 9, 2020
    Inventors: ALCIDES NICASTRO, GUSTAVO M. SOUSS
  • Publication number: 20200009052
    Abstract: Methods and devices for producing a population of liposomes are provided. Aspects of the methods include applying a centrifugal force to a suspension of liposomes in a manner sufficient to pass the liposomes through a porous membrane to produce a population of liposomes. Aspects of the invention further include devices, systems and kits useful for performing the methods.
    Type: Application
    Filed: July 3, 2018
    Publication date: January 9, 2020
    Inventors: Oleg Guryev, Aaron J. Middlebrook, Marybeth Sharkey
  • Publication number: 20200009053
    Abstract: This invention relates to devices, systems and methods for delivering preprogrammed quantities of an active ingredient to a biological system over time without the need for external power or electronics.
    Type: Application
    Filed: February 7, 2019
    Publication date: January 9, 2020
    Inventors: William R. Freeman, Michael J. Sailor, Lingyun Cheng
  • Publication number: 20200009054
    Abstract: A bioactive substance carrier includes a bioactive substance, and porous silica particles supporting the bioactive substance and having a plurality of pores with a diameter of 5 nm to 100 nm. The porous silica particles have particular physical properties, can deliver all various drugs by a supported amount in a sustained manner, and can be parenterally administered.
    Type: Application
    Filed: February 6, 2018
    Publication date: January 9, 2020
    Inventor: Cheolhee WON
  • Publication number: 20200009055
    Abstract: A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the content of the disintegrant is more than 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; wherein the content of the polyalkylene oxide is at least 25 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; and wherein the dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.
    Type: Application
    Filed: July 19, 2019
    Publication date: January 9, 2020
    Applicant: GRÜNENTHAL GMBH
    Inventors: KLAUS WENING, ANJA GEISSLER, JANA DENKER, LUTZ BARNSCHEID
  • Publication number: 20200009056
    Abstract: A pharmaceutical composition comprises octreotide acetate microparticles of linear poly (lactide-co-glycolide) polymer wherein the polymer contains less than 1% silicone oil or heptane.
    Type: Application
    Filed: September 19, 2019
    Publication date: January 9, 2020
    Inventors: Holger Petersen, Olivier Jean Lambert, Rolf Löffler, Michael Ausborn, Jean-Daniel Bonny
  • Publication number: 20200009057
    Abstract: A tablet press comprises a gate that defines a first switching position that feeds tablets into a first tablet outlet and at least a second switching position that feeds tablets into at least one second tablet outlet. The table press further comprises a control apparatus and a drive apparatus. The drive apparatus is configured to be actuated by the control apparatus to move the gate from a home position defined as one of the first switching position and the at least a second switching position into a target position defined as a switching position that is not the home position. The gate is moved from the home switching position at a speed of movement toward the target position such that the speed of movement of the gate is reduced before the target position is reached.
    Type: Application
    Filed: July 1, 2019
    Publication date: January 9, 2020
    Applicant: Fette Compacting GmbH
    Inventors: Friedrich Meissner, Stefan Luedemann
  • Publication number: 20200009058
    Abstract: A tablet press comprises a gate and a control apparatus configured to generate a switching signal. A drive apparatus is configured to move the gate in response to the switching signal received from the control apparatus between a first switching position and at least a second switching position. At least one sensor is configured to generate a detection signal when the gate reaches one of the switching positions. The control apparatus receives the detection signal and is configured to output a switching signal to the drive apparatus to at least partially move the gate back into a home position when there is a switching signal to move the gate out of the home position and there is no detection signal received from the at least one sensor. The control apparatus subsequently outputs a switching signal to again move the gate out of the home position to a target position.
    Type: Application
    Filed: July 1, 2019
    Publication date: January 9, 2020
    Applicant: Fette Compacting GmbH
    Inventors: Friedrich Meissner, Stefan Luedemann
  • Publication number: 20200009059
    Abstract: Compositions and methods for combination therapy are provided. The compositions comprise a multiple unit dosage form having both a therapeutic agent and a nutritional supplement. The combination therapy is useful for restoring a nutrient depletion associated with a particular disease state. Additionally, the combination therapy can prevent or attenuate the depletion of a nutrient caused, in whole or in part, by the co-administrated therapeutic drug. Methods of manufacturing the formulations are likewise described.
    Type: Application
    Filed: July 29, 2019
    Publication date: January 9, 2020
    Inventor: James R. Komorowski
  • Publication number: 20200009060
    Abstract: The disclosure provides for improved pharmaceutical compositions containing an active pharmaceutical ingredient and a non-polymeric lubricant and methods of manufacturing the same. In particular, the compositions are prepared using thermal processing or solvent sprying and provide improved properties as well as more efficient methods of manufacture.
    Type: Application
    Filed: May 8, 2017
    Publication date: January 9, 2020
    Applicant: DISPERSOL TECHNOLOGIES, LLC
    Inventors: Dave A. MILLER, Daniel J. ELLENBERGER, Sandra U. SCHILLING
  • Publication number: 20200009061
    Abstract: The present invention relates to solid, oral dosage forms of asimadoline comprising lactose monohydrate.
    Type: Application
    Filed: June 21, 2019
    Publication date: January 9, 2020
    Applicant: Tioga Pharmaceuticals, Inc.
    Inventor: KOSUKE SHIGETA
  • Publication number: 20200009062
    Abstract: The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.
    Type: Application
    Filed: September 17, 2019
    Publication date: January 9, 2020
    Applicant: Impax Laboratories, Inc.
    Inventors: Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
  • Publication number: 20200009063
    Abstract: The invention provides novel formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use in the treatment of gastrointestinal diseases and disorders, including gastrointestinal cancer. The GCC agonist formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
    Type: Application
    Filed: June 26, 2018
    Publication date: January 9, 2020
    Inventors: Kunwar SHAILUBHAI, Stephen COMISKEY
  • Publication number: 20200009064
    Abstract: The present invention is directed to an immediate release and extended release capsule or capsule fill which mitigates the abuse of abuse-susceptible active pharmaceutical ingredients by direct intravenous injection. The fill comprises a parenteral abuse resistant liquid formulation which when mixed with water and heated, results in a turbid, viscous or bubbling mixture that is not injectable with a standard insulin syringe. The abuse-susceptible active pharmaceutical ingredient is selected from the group consisting of opiates, opioids, tranquilizers, stimulants and narcotics.
    Type: Application
    Filed: September 16, 2019
    Publication date: January 9, 2020
    Applicant: R.P. Scherer Technologies, LLC
    Inventor: Simone Wengner
  • Publication number: 20200009065
    Abstract: Provided herein are various gas-filled particles having a stimuli-responsive shell encapsulating the gas. The stimuli-responsive shell comprises one or more release triggers. Compositions for medical or non-medical applications, methods of use and treatment, and methods of preparation are also described.
    Type: Application
    Filed: February 28, 2018
    Publication date: January 9, 2020
    Applicant: Children's Medical Center Corporation
    Inventors: Brian D. Polizzotti, Yifeng Peng, John Kheir
  • Publication number: 20200009066
    Abstract: The present invention aims to provide a warming composition showing a favorable dispersion stability after long-term storage, a high warming impact, and improvement of zeolite-specific deterioration of feeling of use, and to provide an aerosol formulation containing the warming composition. This object is achieved with a warming composition containing zeolite nanoparticles having an average particle size of not more than 500 nm, wherein the temperature of the composition is rapidly increased by heat generated by hydration reaction between the zeolite and water.
    Type: Application
    Filed: September 13, 2019
    Publication date: January 9, 2020
    Inventors: Hokuto Kamijyo, Yasutomo Nakajima, Toru Wakihara, Yasuo Yonezawa
  • Publication number: 20200009067
    Abstract: Provided is a formulation and method for increasing bioavailability of an orally administered drug.
    Type: Application
    Filed: September 20, 2019
    Publication date: January 9, 2020
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Amnon HOFFMAN, Abraham J. DOMB, Anna ELGART, Irina CHERNIAKOV
  • Publication number: 20200009068
    Abstract: Hypotonic formulations and methods for delivering drugs to bladder, improving drug absorption and retention therein, and minimizing systemic toxicity, are provided. The formulation includes particles formed from the assembly or association between biocompatible polymers with and without low or high grafting density of polyethylene glycol (PEG) and a wide range of drugs. A hypotonic medium or water allows the particles to penetrate and distribute within bladder tissue, where the particles are capable of dissolution to release drugs for absorption and retention. A reduced level of local and systemic toxicity and side effects of the formulation, compared to delivery of drugs in their free form, provides an effective and safe drug delivery platform for treating bladder or associated diseases or disorders.
    Type: Application
    Filed: September 17, 2019
    Publication date: January 9, 2020
    Inventors: Laura Ensign, Justin Hanes, Abhijit Date, Trinity Bivalacqua, Max Kates
  • Publication number: 20200009069
    Abstract: Zwitterionic dendrimers and zwitterionic polymers and methods of making the zwitterionic dendrimers/polymers are provided herein. Also provided are amphiphilic dendrimers and amphiphilic telodendnmers with one or more zwitterionic dendron/polymer/linear group(s)/moiety(s) covalently bonded thereto. The amphiphilic dendrimers and amphiphilic telodendrimers are useful in N protein binding and drug delivery. The amphiphilic dendrimers and amphiphilic telodendrimers are used in methods of treatment and/or imaging.
    Type: Application
    Filed: February 28, 2018
    Publication date: January 9, 2020
    Inventors: Juntao LUO, Lili WANG, Changying SHI
  • Publication number: 20200009070
    Abstract: A method for intracellular delivery of single proteins or other cargo molecules by encapsulation within nanocapsules formed by interfacial polymerization of one or more types of monomers and selected protease cleavable cross-linkers is provided. The thin positively charged capsules are readily brought into the cytosol of target cells by endocytosis. The capsules are degraded by the action of endogenous proteases or co-delivered proteases on the cross-linkers releasing the functional cargo unaltered. The cross-linkers can be adapted to be cleavable by specific enzymes selected from available intracellular enzymes within the target cell or co-delivered or self-cleaving when the cargo itself is a protease. The nanocapsules produced by the methods have been shown to have long-term stability, high cell penetration capability, low toxicity and efficient protease-modulated specific degradability without affecting cargo protein function.
    Type: Application
    Filed: August 26, 2019
    Publication date: January 9, 2020
    Applicant: The Regents of the University of California
    Inventors: Yi Tang, Zhen Gu, Yunfeng Lu, Ming Yan, Anuradha Biswas, Guoping Fan
  • Publication number: 20200009071
    Abstract: The present invention relates generally to compositions and methods comprising abiotic, synthetic polymer nanoparticles (NPs) with affinity and specificity to peptide toxins, enzymes, signaling proteins and other large biomacromolecules. The synthetic polymer NPs are an improvement over the current art due to insusceptibility to phospholipase attack, a mechanism common to many venoms. In one embodiment, the compositions and methods relate to synthetic polymer NPs with affinity and specificity to three finger toxins (3FTX) and phospholipase A2. In one embodiment, the compositions and methods are useful for delaying or preventing tissue necrosis due to envenomation.
    Type: Application
    Filed: December 15, 2017
    Publication date: January 9, 2020
    Inventors: Kenneth J. Shea, Jeff O'Brien
  • Publication number: 20200009072
    Abstract: A bioelectrode sheet (100) is configured to be affixed to the skin of a subject, a drug (104b) being mixed in an adhesive layer (104) provided at a peripheral position of a conductive gel layer (103) so as to avoid the conductive gel layer (103). The drug (104b) admixed with the adhesive layer (104) can thereby be caused to penetrate the body while biological information is acquired by an electrode (102) via the conductive gel layer (103).
    Type: Application
    Filed: March 14, 2018
    Publication date: January 9, 2020
    Inventor: Yutaka FUKUDA
  • Publication number: 20200009073
    Abstract: The present invention is directed to transdermal therapeutic systems that are free of fibrous constituents, as well methods for producing such transdermal therapeutic systems. A preparation containing active substance is applied by a printing method onto the pressure-sensitive adhesive layer of the transdermal therapeutic system. Exemplary printing methods include application methods based upon a distributor plate of an application device.
    Type: Application
    Filed: September 20, 2019
    Publication date: January 9, 2020
    Inventors: Reinhold Meconi, Klaus Schumann
  • Publication number: 20200009074
    Abstract: [Problem] To provide a supplement in a new form by which the targeted component is made available for intake other than the oral intake. [Solution] A patch-type supplement composed of a support, a component-containing layer, and a release liner, and the component-containing layer containing a supplement component and an adhesive. The adhesive is preferably an acrylate-based adhesive. A water vapor permeability of the support is preferably not larger than 1000 g/m2×24 hours. The supplement component is preferably made of an aqueous component and an organic component.
    Type: Application
    Filed: June 30, 2019
    Publication date: January 9, 2020
    Inventors: Hiroshi Tanaka, Ying-shu Quan, Junya Hasegawa, Fumio Kamiyama
  • Publication number: 20200009075
    Abstract: A patch base comprises gelatin, polyvinyl alcohol, a methyl acrylate/2-ethylhexyl acrylate copolymer, and L-menthyl glyceryl ether, wherein relative to the total mass of the base, the content of the gelatin is 1.5 to 6% by mass, the content of the polyvinyl alcohol is 0.5 to 8% by mass, and the content of the methyl acrylate/2-ethylhexyl acrylate copolymer is 0.5 to 13% by mass.
    Type: Application
    Filed: February 15, 2018
    Publication date: January 9, 2020
    Applicant: HISAMITSU PHARMACEUTICAL CO., INC.
    Inventors: Keiichiro TSURUSHIMA, Masakazu SAEKI, Takaaki YOSHINAGA
  • Publication number: 20200009076
    Abstract: The disclosure provides a pharmaceutical composition of phloroglucinol and/or trimethylphloroglucinol and/or a pharmaceutically acceptable salt thereof for oral administration to a patient.
    Type: Application
    Filed: March 8, 2018
    Publication date: January 9, 2020
    Applicant: CinRx Pharma, LLC
    Inventors: Piyush PATEL, Catherine PEARCE, John ISAACSOHN
  • Publication number: 20200009077
    Abstract: Embodiments of the invention are directed to compositions containing cannabinoid, cannabidiol, cannabidiol isomer, or cannabidiol analog and combinations thereof for treating dermatological disease, and methods for treating dermatological diseases by administering compositions containing cannabinoid, cannabidiol, or cannabidiol analog to the skin of a patient in need of treatment.
    Type: Application
    Filed: July 3, 2019
    Publication date: January 9, 2020
    Applicant: TRUETIVA, Inc.
    Inventor: J. Phillip KENNEDY
  • Publication number: 20200009078
    Abstract: Embodiments of the invention are directed to compositions containing cannabinoid, cannabidiol, cannabidiol isomer, or cannabidiol analog and combinations thereof for treating dermatological disease, and methods for treating dermatological diseases by administering compositions containing cannabinoid, cannabidiol, or cannabidiol analog to the skin of a patient in need of treatment.
    Type: Application
    Filed: July 3, 2019
    Publication date: January 9, 2020
    Applicant: TRUETIVA, Inc.
    Inventor: J. Phillip KENNEDY
  • Publication number: 20200009079
    Abstract: Described herein are methods, compositions, systems, and kits that effectively deliver a laxative to a patient along with effective electrolyte replenishment by delivering both a laxative and electrolytes via a food item. The food item is prepared by either combining, mixing, or integrating the ingredients that form the food item together with one of or both of a laxative and electrolytes so that the ingredients in the food item either eliminate or significantly reduce the poor taste associated with either the electrolytes or the laxative. Eliminating or reducing the poor taste associated with either electrolytes or laxative, greatly improves patient satisfaction and compliance with ingesting these substances in order to, for example, prepare the GI tract of the patient for a medical or surgical procedure.
    Type: Application
    Filed: September 16, 2019
    Publication date: January 9, 2020
    Inventors: Michael ALLIO, Jonathan GORDON
  • Publication number: 20200009080
    Abstract: The invention relates to a transmucosal delivery system for idebenone, comprising an external phase, which contains at least one hydrophilic polymer, and an inner hydrophobic phase, which contains idebenone and at least one hydrophobic substance, wherein the inner hydrophobic phase is emulsified in the form of droplets in the external phase. The invention is characterized in that the inner hydrophobic phase is stabilized by at least one emulsifier in the external phase. The invention also relates to a method for producing the same and its use as a medicament.
    Type: Application
    Filed: February 28, 2018
    Publication date: January 9, 2020
    Inventors: Michael LINN, Markus MULLER, Marius BAUER
  • Publication number: 20200009081
    Abstract: The present invention provides devices and methods for treating depression in a patient, comprising administering to the patient in need of the treatment a therapeutically effective amount of esketamine. In some embodiments, the depression is major depressive disorder or treatment resistant depression. In other embodiments, the therapeutically effective amount is clinically proven safe and/or effective. Also provided are methods to mitigate the risk or misuse or abuse of esketamine, instructions for use of the esketamine product, and methods for selling a drug product containing esketamine.
    Type: Application
    Filed: June 13, 2019
    Publication date: January 9, 2020
    Inventors: Jingli Wang, Michael Cannamela, Hong Yan, Rochelle Kleinberg
  • Publication number: 20200009082
    Abstract: The present invention relates to an abuse-proofed oral dosage form with controlled release of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which comprises the active ingredient and/or one or more of the pharmaceutically acceptable salts thereof (A), at least one synthetic or natural polymer (C), delayed-release auxiliary substances, optionally physiologically acceptable auxiliary substances (B) and optionally a wax (D), component (C) or (D) in each case exhibiting a breaking strength of at least 500 N, preferably of at least 1000 N.
    Type: Application
    Filed: July 19, 2019
    Publication date: January 9, 2020
    Applicant: GRÜNENTHAL GMBH
    Inventors: Johannes BARTHOLOMÄUS, Heinrich KUGELMANN, Elisabeth ARKENAU-MARIC
  • Publication number: 20200009083
    Abstract: The use of tapentadol in the treatment of pain and/or pain chronification in a subject suffering from pain chronification and/or in the treatment of pain and inhibition of pain chronification in a subject suffering from pain and at risk of pain chronification, as well as the use of tapentadol for the treatment or inhibition of migraine.
    Type: Application
    Filed: July 19, 2019
    Publication date: January 9, 2020
    Applicant: Grünenthal GmbH
    Inventors: Klaus SCHIENE, Ilona STEIGERWALD, Michel HAMON, Johannes SCHNEIDER, Silvia REINARTZ, Ulrich JAHNEL, Thomas TZSCHENTKE
  • Publication number: 20200009084
    Abstract: Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
    Type: Application
    Filed: August 23, 2019
    Publication date: January 9, 2020
    Inventors: Suzanne E. Wardell, Erik R. Nelson, Donald P. McDonnell
  • Publication number: 20200009085
    Abstract: Methods of treating ovarian cancer are disclosed.
    Type: Application
    Filed: September 27, 2017
    Publication date: January 9, 2020
    Inventor: Gary Hattersley
  • Publication number: 20200009086
    Abstract: The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo.
    Type: Application
    Filed: February 15, 2019
    Publication date: January 9, 2020
    Inventors: Xianqi KONG, Mohamed ATFANI, Benoit BACHAND, Abderrahim BOUZIDE, Stephane CIBLAT, Sophie LEVESQUE, David MIGNEAULT, Isabelle VALADE, Xinfu WU, Daniel DELORME